Score:
9.5/15
Analyze what earned this score 🔥
Topper’s Copy
GS3
Economy
15 marks
India's pharmaceutical industry is increasingly becoming a strategic pillar of the economy and global healthcare. In this context, examine the implications of the proposed U.S. tariffs on generic medicines for India's pharmaceutical sector and discuss the policy measures needed to strengthen its global competitiveness.
Student’s Answer
Evaluation by SuperKalam
Demand of the Question
- Examine implications of proposed U.S. tariffs on generic medicines for India's pharmaceutical sector
- Discuss policy measures needed to strengthen global competitiveness of India's pharma industry
What you wrote:
The Indian pharmaceutical industry, recognized globally as 'Pharmacy of the world', supplies over 20% of global generic medicines. However, the proposed US tariff announces phased tariff structure targeting imported generic drugs. Announcement ⇒ July 2026. Grace Period (0% tariff) ⇒ August 2026 - August 2028 100% tariff ⇒ August 2028 - August 2029 200% tariff (Permanent) ⇒ August 2029 onwards
The Indian pharmaceutical industry, recognized globally as 'Pharmacy of the world', supplies over 20% of global generic medicines. However, the proposed US tariff announces phased tariff structure targeting imported generic drugs. Announcement ⇒ July 2026. Grace Period (0% tariff) ⇒ August 2026 - August 2028 100% tariff ⇒ August 2028 - August 2029 200% tariff (Permanent) ⇒ August 2029 onwards
Suggestions to improve:
- Could enhance by briefly defining India's pharmaceutical sector scope (e.g., $50 billion industry employing 3 million people directly) to establish economic significance before diving into tariff details.
What you wrote:
# Implications of Proposed US tariff on India's Pharma Sector 1. Squeezing of Profit Margins - US is India's largest market, accounting for 37% of its pharma exports. Tariffs will compress the margins of Indian generic drugs. 2. 'Cost Arbitrage' - Many Indian generics are priced 7 to 10 times lower than branded US alternates. Indian exporters may retain market access by partially passing on costs. 3. Forced Capital Realignment - Indian companies will face intense pressure to shift from domestic manufacturing to high cost US-based brownfield acquisitions or local contract development & manufacturing organizations.
# Implications of Proposed US tariff on India's Pharma Sector 1. Squeezing of Profit Margins - US is India's largest market, accounting for 37% of its pharma exports. Tariffs will compress the margins of Indian generic drugs. 2. 'Cost Arbitrage' - Many Indian generics are priced 7 to 10 times lower than branded US alternates. Indian exporters may retain market access by partially passing on costs. 3. Forced Capital Realignment - Indian companies will face intense pressure to shift from domestic manufacturing to high cost US-based brownfield acquisitions or local contract development & manufacturing organizations.
Suggestions to improve:
- Could analyze employment implications (e.g., pharmaceutical sector employs 3 million directly, with tariffs potentially affecting 500,000 jobs in export-oriented units)
- Could examine global healthcare access concerns (e.g., WHO estimates 2 billion people rely on Indian generic medicines for affordable treatment)
What you wrote:
# Policy Measures to strengthen Global Competitiveness 1. Enhance PLI schemes - Pivot the existing PLI scheme towards high-value segments like Biosimilars, Complex Generics & Orphan Drugs, where higher margins can absorb external tariff shocks. 2. Market Diversification via FTAs - Actively conclude ongoing FTA with EU, UK, Latin American blocs to dilute 37% export concentration risk in US. 3. Transition to an innovation led ecosystem through sovereign R&D funding with establishment of National Pharma Research Fund.
# Policy Measures to strengthen Global Competitiveness 1. Enhance PLI schemes - Pivot the existing PLI scheme towards high-value segments like Biosimilars, Complex Generics & Orphan Drugs, where higher margins can absorb external tariff shocks. 2. Market Diversification via FTAs - Actively conclude ongoing FTA with EU, UK, Latin American blocs to dilute 37% export concentration risk in US. 3. Transition to an innovation led ecosystem through sovereign R&D funding with establishment of National Pharma Research Fund.
Suggestions to improve:
- Could include regulatory reforms (e.g., fast-track drug approval processes through Central Drugs Standard Control Organisation to reduce time-to-market from 2-3 years to 12-18 months)
- Could mention infrastructure development (e.g., establishing pharmaceutical parks with integrated supply chains and quality testing facilities)
- Could discuss skill development initiatives (e.g., specialized training programs for pharmaceutical R&D through collaboration with IITs and pharmaceutical universities)
What you wrote:
The proposed US tariff shows vulnerability of pharma in global markets. By swiftly executing structural reforms - transitioning from 'Make in India' to 'Discover & Innovate in India' - the domestic pharma sector can turn this protectionist challenge into an opportunity to secure long term, resilient leadership.
The proposed US tariff shows vulnerability of pharma in global markets. By swiftly executing structural reforms - transitioning from 'Make in India' to 'Discover & Innovate in India' - the domestic pharma sector can turn this protectionist challenge into an opportunity to secure long term, resilient leadership.
Suggestions to improve:
- Could strengthen by linking to broader economic goals (e.g., achieving $130 billion pharmaceutical industry target by 2030 while maintaining global leadership in affordable healthcare access) to provide concrete aspirational context.
Your answer demonstrates strong analytical skills with excellent use of current data and strategic thinking. The tariff timeline breakdown and economic impact analysis are particularly well-executed, showing deep understanding of the pharmaceutical sector's global dynamics.
Demand of the Question
- Examine implications of proposed U.S. tariffs on generic medicines for India's pharmaceutical sector
- Discuss policy measures needed to strengthen global competitiveness of India's pharma industry
What you wrote:
The Indian pharmaceutical industry, recognized globally as 'Pharmacy of the world', supplies over 20% of global generic medicines. However, the proposed US tariff announces phased tariff structure targeting imported generic drugs. Announcement ⇒ July 2026. Grace Period (0% tariff) ⇒ August 2026 - August 2028 100% tariff ⇒ August 2028 - August 2029 200% tariff (Permanent) ⇒ August 2029 onwards
The Indian pharmaceutical industry, recognized globally as 'Pharmacy of the world', supplies over 20% of global generic medicines. However, the proposed US tariff announces phased tariff structure targeting imported generic drugs. Announcement ⇒ July 2026. Grace Period (0% tariff) ⇒ August 2026 - August 2028 100% tariff ⇒ August 2028 - August 2029 200% tariff (Permanent) ⇒ August 2029 onwards
Suggestions to improve:
- Could enhance by briefly defining India's pharmaceutical sector scope (e.g., $50 billion industry employing 3 million people directly) to establish economic significance before diving into tariff details.
More Challenges
View All- View Challenge
GS2
International Relations
10 Oct, 2026
Recent restrictions on H-1B visas by the United States have raised concerns for Indian professionals. Discuss their implications for India and suggest measures to address these challenges.
- View Challenge
GS3
Environment & Ecology
Yesterday
The Living Planet Report highlights a sharp decline in wildlife populations worldwide. What does this decline actually indicate? Discuss the major causes of biodiversity loss and suggest conservation measures.
- View Challenge
GS3
Economy
8 Oct, 2026
How does a repo rate hike help control inflation? Discuss its impact on the Indian economy.
SuperKalam is your personal mentor for UPSC preparation, guiding you at every step of the exam journey.
Download the App
STUDY RESOURCES
CONTACT US
ⓒ Snapstack Technologies Private Limited